Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02)

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Inflammation and cancer

2002 • 14,174 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 • 3,395 citations

Head and Neck Cancer

1993 • 2,263 citations

X-linked IAP is a direct inhibitor of cell-death proteases

1997 • 1,961 citations

Epidermal growth factor receptor (EGFR) signaling in cancer

2005 • 1,852 citations

Insulin-like growth factors and neoplasia

2004 • 1,452 citations

Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival

1998 • 1,083 citations

Epidermal Growth Factor Receptor Biology in Head and Neck Cancer

2006 • 687 citations

The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo.

1995 • 385 citations

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

2009 • 373 citations

Identification of suitable internal control genes for expression studies in Coffea arabica under different experimental conditions

2009 • 365 citations

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

2009 • 334 citations

Critical Role of Endogenous Akt/IAPs and MEK1/ERK Pathways in Counteracting Endoplasmic Reticulum Stress-induced Cell Death

2004 • 319 citations

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

2009 • 301 citations

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

2009 • 269 citations

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

2007 • 268 citations

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

2009 • 267 citations

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

2011 • 238 citations

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

2008 • 205 citations

A Retrospective Analysis of the Outcome of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Refractory to a Platinum-based Chemotherapy

2005 • 173 citations

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

2009 • 170 citations

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

2008 • 165 citations

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

2009 • 149 citations

The insulin-like growth factor-I receptor as a target for cancer therapy

2005 • 146 citations

Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer

2007 • 143 citations

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer

2010 • 139 citations

Targeting insulin-like growth factor pathways

2006 • 114 citations

Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers

2008 • 110 citations

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924

2008 • 100 citations

Inflammation and Cancer

2006 • 82 citations

Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.

2009 • 81 citations

Reference gene selection for head and neck squamous cell carcinoma gene expression studies

2009 • 56 citations

A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors

2008 • 55 citations

cIAP2 as a therapeutic target in colorectal cancer and other malignancies

2009 • 55 citations

Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases

2011 • 44 citations

Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and α2-macroglobulin in cases of generalized AA- and AL amyloidosis

2000 • 36 citations

Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells

2011 • 21 citations

An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).

2010 • 14 citations

Aberrant expression of serum amyloid A in head and neck squamous cell carcinoma

2009 • 9 citations

Clinical significance of type 1 insulin-like growth factor receptor and insulin-like growth factor binding protein-3 expression in squamous cell carcinoma of head and neck

2009 • 7 citations